Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 7
2020 7
2021 9
2022 8
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean charlier bergen (2 results)?
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.
Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L, Milonas D, Van Poppel H, Berghen C, Everaerts W, Claessens F, Joniau S. Devos G, et al. Among authors: berghen c. Nat Rev Urol. 2021 Dec;18(12):739-762. doi: 10.1038/s41585-021-00514-9. Epub 2021 Sep 15. Nat Rev Urol. 2021. PMID: 34526701 Review.
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G, Tosco L, Baldewijns M, Gevaert T, Goffin K, Petit V, Mai C, Laenen A, Raskin Y, Van Haute C, Goeman L, De Meerleer G, Berghen C, Devlies W, Claessens F, Van Poppel H, Everaerts W, Joniau S. Devos G, et al. Among authors: berghen c. Eur Urol. 2023 Jun;83(6):508-518. doi: 10.1016/j.eururo.2022.09.009. Epub 2022 Sep 24. Eur Urol. 2023. PMID: 36167599 Clinical Trial.
Elective nodal radiotherapy in prostate cancer.
De Meerleer G, Berghen C, Briganti A, Vulsteke C, Murray J, Joniau S, Leliveld AM, Cozzarini C, Decaestecker K, Rans K, Fonteyne V, De Hertogh O, Bossi A. De Meerleer G, et al. Among authors: berghen c. Lancet Oncol. 2021 Aug;22(8):e348-e357. doi: 10.1016/S1470-2045(21)00242-4. Lancet Oncol. 2021. PMID: 34339655 Review.
Current and emerging therapies for localized high-risk prostate cancer.
Moris L, Devos G, Van den Broeck T, Milonas D, Albersen M, Berghen C, De Meerleer G, Devlies W, Everaerts W, Gevaert T, Van Poppel H, Claessens F, Joniau S. Moris L, et al. Among authors: berghen c. Expert Rev Anticancer Ther. 2021 Mar;21(3):267-282. doi: 10.1080/14737140.2021.1852932. Epub 2020 Dec 22. Expert Rev Anticancer Ther. 2021. PMID: 33225759 Review.
In Regard to Zelefsky et al.
Rans K, De Meerleer G, Joniau S, Baten A, Berkovic P, Lambrecht M, Berghen C. Rans K, et al. Among authors: berghen c. Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):910-911. doi: 10.1016/j.ijrobp.2021.02.038. Int J Radiat Oncol Biol Phys. 2021. PMID: 34089682 No abstract available.
Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
Milenkovic U, Kuijk J, Roussel E, Devos G, Van den Broeck T, Van Eecke H, Vanderstichele A, Duvillier T, Verhamme L, Van Haute W, Goeman L, Berghen C, Joniau S, De Meerleer G. Milenkovic U, et al. Among authors: berghen c. Eur Urol Oncol. 2023 Dec;6(6):582-589. doi: 10.1016/j.euo.2023.02.010. Epub 2023 Mar 4. Eur Urol Oncol. 2023. PMID: 36878753
Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study.
Fonteyne V, Danckaert W, Ost P, Berghen C, Vandecasteele K, Vanneste B, Rans K, Liefhooghe N, Wallaert S, Paelinck L. Fonteyne V, et al. Among authors: berghen c. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231154088. doi: 10.1177/15330338231154088. Technol Cancer Res Treat. 2023. PMID: 37016933 Free PMC article. Clinical Trial.
34 results